Elanco Animal Health Incorporated (ELAN)
NYSE: ELAN · Real-Time Price · USD
22.12
-0.15 (-0.67%)
At close: Oct 28, 2025, 4:00 PM EDT
22.35
+0.23 (1.03%)
After-hours: Oct 28, 2025, 7:42 PM EDT
Elanco Animal Health Revenue
Elanco Animal Health had revenue of $1.24B in the quarter ending June 30, 2025, with 4.81% growth. This brings the company's revenue in the last twelve months to $4.48B, down -0.18% year-over-year. In the year 2024, Elanco Animal Health had annual revenue of $4.44B with 0.50% growth.
Revenue (ttm)
$4.48B
Revenue Growth
-0.18%
P/S Ratio
2.44
Revenue / Employee
$474,497
Employees
9,450
Market Cap
10.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.44B | 22.00M | 0.50% |
| Dec 31, 2023 | 4.42B | 6.00M | 0.14% |
| Dec 31, 2022 | 4.41B | -353.00M | -7.41% |
| Dec 31, 2021 | 4.76B | 1.49B | 45.64% |
| Dec 31, 2020 | 3.27B | 200.00M | 6.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ELAN News
- 1 day ago - Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species - PRNewsWire
- 4 days ago - Elanco gets US FDA emergency nod for dog drug as threat of flesh-eating parasite looms - Reuters
- 4 days ago - Elanco Animal Health Obtains FDA Authorization for Screwworm Treatment - WSJ
- 4 days ago - Elanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs - PRNewsWire
- 12 days ago - Elanco to Host Investor Day on December 9 - PRNewsWire
- 27 days ago - Elanco Confirms Date and Conference Call for Third Quarter 2025 Financial Results Announcement - PRNewsWire
- 5 weeks ago - Elanco Announces FDA Approves Improved Zenrelia™ (ilunocitinib tablets) Label, Removing Vaccine-Induced Disease Language - PRNewsWire
- 7 weeks ago - Elanco Animal Health Incorporated (ELAN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha